Clinical Trial Update: Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma [Phase 1, Phase 2]

View source ↗

Summary

A randomized Phase 1/2 study evaluating TPI-287 for primary refractory or early relapsed neuroblastoma was terminated. Results were posted in October 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• TPI-287

Snippet

Sponsor: Giselle Sholler | Conditions: Neuroblastoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-10-28